(GERN) Geron - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 828m USD | Total Return: -13.5% in 12m
Avg Turnover: 18.5M
Qual. Beats: 1
Rev. Trend: 92.7%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -1.3 is critical
Altman Z'' -13.04 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing telomerase inhibitors for hematologic malignancies. Its lead product, RYTELO, targets adult patients with transfusion-dependent anemia associated with lower-risk myelodysplastic syndromes (MDS). The company maintains an extensive clinical pipeline, including Phase 3 trials for relapsed/refractory myelofibrosis and various early-stage studies for acute myeloid leukemia.
Operating within the biotechnology sector, Geron utilizes a high-risk, high-reward business model characterized by significant research and development expenditures prior to regulatory approval. Telomerase inhibition represents a specialized therapeutic approach designed to limit the proliferative capacity of malignant stem cells. Investors may find further insights on sector performance and valuation metrics at ValueRay.
- RYTELO commercial adoption rates drive near-term revenue growth and cash flow
- IMpactMF Phase 3 clinical trial results determine expansion into myelofibrosis market
- Regulatory approvals for IMerge in international jurisdictions influence long-term valuation
- High research and development expenses pressure margins during commercial launch phase
- Competitive landscape in myelodysplastic syndrome treatments impacts RYTELO market share capture
| Net Income: -69.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA 12.70 > 1.0 |
| NWC/Revenue: 216.7% < 20% (prev 372.1%; Δ -155.4% < -1%) |
| CFO/TA -0.24 > 3% & CFO -126.0m > Net Income -69.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (669.4m) vs 12m ago 0.52% < -2% |
| Gross Margin: 86.59% > 18% (prev 0.98%; Δ 8.56k% > 0.5%) |
| Asset Turnover: 35.77% > 50% (prev 20.68%; Δ 15.09% > 0%) |
| Interest Coverage Ratio: -1.32 > 6 (EBITDA TTM -40.7m / Interest Expense TTM 31.6m) |
| A: 0.80 (Total Current Assets 498.5m - Total Current Liabilities 73.6m) / Total Assets 534.1m |
| B: -3.48 (Retained Earnings -1.86b / Total Assets 534.1m) |
| C: -0.08 (EBIT TTM -41.7m / Avg Total Assets 548.3m) |
| D: -6.09 (Book Value of Equity -1.86b / Total Liabilities 305.0m) |
| Altman-Z'' = -13.04 = D |
| DSRI: 0.77 (Receivables 44.1m/34.0m, Revenue 196.1m/116.3m) |
| GMI: 1.13 (GM 86.59% / 97.88%) |
| AQI: 0.58 (AQ_t 0.06 / AQ_t-1 0.11) |
| SGI: 1.69 (Revenue 196.1m / 116.3m) |
| TATA: 0.11 (NI -69.6m - CFO -126.0m) / TA 534.1m) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of May 23, 2026, the stock is trading at USD 1.26 with a total of 8,141,795 shares traded.
Over the past week, the price has changed by -0.78%,
over one month by -17.42%,
over three months by -27.68% and
over the past year by -13.51%.
Geron has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy GERN.
- StrongBuy: 4
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 3.4 | 169.8% |
P/B = 3.8921
P/EG = -2.38
Revenue TTM = 196.1m USD
EBIT TTM = -41.7m USD
EBITDA TTM = -40.7m USD
Long Term Debt = 119.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 20.4m USD (from shortTermDebt, last quarter)
Debt = 254.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.44m
Net Debt = -60.0m USD (calculated: Debt 254.3m - CCE 314.3m)
Enterprise Value = 767.6m USD (827.6m + Debt 254.3m - CCE 314.3m)
Interest Coverage Ratio = -1.32 (Ebit TTM -41.7m / Interest Expense TTM 31.6m)
EV/FCF = -6.08x (Enterprise Value 767.6m / FCF TTM -126.3m)
FCF Yield = -16.45% (FCF TTM -126.3m / Enterprise Value 767.6m)
FCF Margin = -64.40% (FCF TTM -126.3m / Revenue TTM 196.1m)
Net Margin = -35.48% (Net Income TTM -69.6m / Revenue TTM 196.1m)
Gross Margin = 86.59% ((Revenue TTM 196.1m - Cost of Revenue TTM 26.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.44 (Enterprise Value 767.6m / Total Assets 534.1m)
Interest Expense / Debt = 2.81% (Interest Expense 7.15m / Debt 254.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -33.0m (EBIT -41.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.78 (Total Current Assets 498.5m / Total Current Liabilities 73.6m)
Debt / Equity = 1.11 (Debt 254.3m / totalStockholderEquity, last quarter 229.1m)
Debt / EBITDA = 1.47 (negative EBITDA) (Net Debt -60.0m / EBITDA -40.7m)
Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -60.0m / FCF TTM -126.3m)
Total Stockholder Equity = 240.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.69% (Net Income -69.6m / Total Assets 534.1m)
RoE = -3.31% (Net Income TTM -69.6m / Total Stockholder Equity 2.10b)
RoCE = -1.88% (EBIT -41.7m / Capital Employed (Equity 2.10b + L.T.Debt 119.5m))
RoIC = -19.78% (negative operating profit) (NOPAT -33.0m / Invested Capital 166.7m)
WACC = 7.22% (E(827.6m)/V(1.08b) * Re(8.76%) + D(254.3m)/V(1.08b) * Rd(2.81%) * (1-Tc(0.21)))
Discount Rate = 8.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 5.38%
[DCF] Fair Price = unknown (Cash Flow -126.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.50 | # QB: 1
Revenue Correlation: 92.72 | Revenue CAGR: 1.89k% | SUE: 0.22 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.01 | Chg30d=N/A | Revisions=+20% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.01 | Chg30d=N/A | Revisions=N/A | Analysts=2
EPS current Year (2026-12-31): EPS=-0.02 | Chg30d=+53.81% | Revisions=+20% | GrowthEPS=+84.6% | GrowthRev=+27.1%
EPS next Year (2027-12-31): EPS=0.07 | Chg30d=-12.50% | Revisions=-20% | GrowthEPS=+400.0% | GrowthRev=+42.5%
[Analyst] Revisions Ratio: +20%